3647 results for «604»
3647 results
M-TEER for primary mitral regurgitation
08 Feb 2025 – From PCR Tokyo Valves 2025
In this PCR Tokyo Valves 2025 session on M-TEER for primary mitral regurgitation, gain valuable insights starting with an overview of current TEER devices. Benefit from four case studies that highlight the features of these devices, explore strategies to prevent mitral regurgitation recurrence post-TEER, and delve...
M-TEER around the world
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore the latest insights and advancements in the field of Mitral Transcatheter Edge-to-Edge Repair (M-TEER) from around the world. Discover a new anatomical risk score for predicting procedural outcomes, two-year outcomes from the MiCLASP study, the impact of regurgitant volume to left atrial volume ratio on...
M-TEER difficult situation: small mitral valves, P2 prolapse & leaflet degeneration
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore a series of challenging cases in Mitral Transcatheter Edge-to-Edge Repair (M-TEER), highlighting the versatility and adaptability of this technique. Discover how M-TEER can be successfully applied in patients with extremely small mitral valves, P2 prolapse supported by chordae from the posterior papillary muscle, wide prolapse...
TAVI complications: hemolytic anemia, prosthetic valve endocarditis & stroke
08 Feb 2025 – From PCR Tokyo Valves 2025
Gain valuable insights into the management of complications associated with Transcatheter Aortic Valve Implantation (TAVI). Discover the latest evidence on hemolytic anemia, the predictive value of the hemoglobin to creatinine ratio, outcomes of transcarotid TAVI, a case study on prosthetic valve endocarditis, the role of diastolic...
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.
Author
Author
